Randomized trial of vitamin D supplementation for winter-related atopic dermatitis in children - 02/10/14
, D. Ganmaa, MD, PhD a, b, Robert Sidbury, MD, MPH d, Kh. Erdenedelger, MD b, c, N. Radnaakhand, MD, PhD b, B. Khandsuren, MD, PhD b, cAbstract |
Background |
Epidemiologic and preclinical data, and a small randomized trial in Boston, suggest that vitamin D supplementation may improve winter-related atopic dermatitis (AD).
Objective |
To determine the effect of vitamin D supplementation on winter-related AD.
Methods |
We performed a randomized, double-blind, placebo-controlled trial of Mongolian children with winter-related AD (clinicaltrials.gov identifier: NCT00879424). Baseline eligibility included age 2 to 17 years, AD score 10 to 72 using the Eczema Area and Severity Index (EASI), and winter-related AD (eg, history of AD worsening during the fall-to-winter transition). Subjects were enrolled in Ulaanbaatar during winter and randomly assigned to oral cholecalciferol (1000 IU/day) versus placebo for 1 month. All children and parents received emollient and patient education about AD and basic skin care. The main outcomes were changes in EASI score and in Investigator's Global Assessment.
Results |
The 107 enrolled children had a mean age of 9 years (SD 5), and 59% were male. Their median age of AD onset was 3 months (interquartile range 2 months to 1 year) and mean EASI score at baseline 21 (SD 9). One-month follow-up data were available for 104 (97%) children. Compared with placebo, vitamin D supplementation for 1 month produced a clinically and statistically significant improvement in EASI score (adjusted mean change: −6.5 vs −3.3, respectively; P = .04). Moreover, change in Investigator's Global Assessment favored vitamin D over placebo (P = .03). There were no adverse effects in either group.
Conclusion |
Vitamin D supplementation improved winter-related AD among Mongolian children, a population likely to have vitamin D deficiency in winter.
Le texte complet de cet article est disponible en PDF.Key words : Randomized controlled trial, vitamin D, nutritional supplement, atopic dermatitis, winter, children, Mongolia
Abbreviations used : 25(OH)D, AD, EASI, IGA, IQR, RCT
Plan
| This trial was supported by Massachusetts General Hospital in Boston. Study agents and packaging were provided by Ddrops Company (Toronto, Ontario, Canada). Neither sponsor had any role in the design and conduct of the study; in the collection, analysis, and interpretation of the data; nor in the preparation, review, or approval of the manuscript. |
|
| Disclosure of potential conflict of interest: The authors declare that they have no relevant conflicts of interest. |
Vol 134 - N° 4
P. 831 - octobre 2014 Retour au numéro
Article précédent
- Application of moisturizer to neonates prevents development of atopic dermatitis
- Kenta Horimukai, Kumiko Morita, Masami Narita, Mai Kondo, Hiroshi Kitazawa, Makoto Nozaki, Yukiko Shigematsu, Kazue Yoshida, Hironori Niizeki, Ken-ichiro Motomura, Haruhiko Sago, Tetsuya Takimoto, Eisuke Inoue, Norio Kamemura, Hiroshi Kido, Junzo Hisatsune, Motoyuki Sugai, Hiroyuki Murota, Ichiro Katayama, Takashi Sasaki, Masayuki Amagai, Hideaki Morita, Akio Matsuda, Kenji Matsumoto, Hirohisa Saito, Yukihiro Ohya
- MicroRNA-146a alleviates chronic skin inflammation in atopic dermatitis through suppression of innate immune responses in keratinocytes
- Ana Rebane, Toomas Runnel, Alar Aab, Julia Maslovskaja, Beate Rückert, Maya Zimmermann, Mario Plaas, Jaanika Kärner, Angela Treis, Maire Pihlap, Uku Haljasorg, Helen Hermann, Nikoletta Nagy, Lajos Kemeny, Triin Erm, Külli Kingo, Mei Li, Mark P. Boldin, Cezmi A. Akdis
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?